HC Wainwright Issues Optimistic Estimate for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Relay Therapeutics in a research report issued on Tuesday, May 26th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.36) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($1.50) EPS.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.58 million.

RLAY has been the subject of several other research reports. The Goldman Sachs Group upped their target price on shares of Relay Therapeutics from $13.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Citigroup reissued an “outperform” rating on shares of Relay Therapeutics in a research note on Wednesday, May 20th. Wells Fargo & Company increased their price target on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Oppenheimer increased their price target on Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. Finally, Citizens Jmp increased their price target on Relay Therapeutics from $19.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $23.30.

Relay Therapeutics Stock Performance

NASDAQ:RLAY opened at $14.43 on Thursday. The stock’s fifty day moving average price is $12.95 and its two-hundred day moving average price is $9.91. Relay Therapeutics has a 52-week low of $2.83 and a 52-week high of $17.32. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -9.19 and a beta of 1.74.

Institutional Trading of Relay Therapeutics

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Relay Therapeutics by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after purchasing an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Relay Therapeutics by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after purchasing an additional 5,238 shares in the last quarter. Millennium Management LLC increased its holdings in Relay Therapeutics by 14.6% during the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Relay Therapeutics during the 1st quarter worth about $53,000. Finally, Woodline Partners LP increased its holdings in Relay Therapeutics by 448.4% during the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after purchasing an additional 1,241,657 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Insider Activity at Relay Therapeutics

In related news, CFO Thomas Catinazzo sold 17,717 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the completion of the sale, the chief financial officer owned 195,178 shares in the company, valued at $2,509,989.08. This represents a 8.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 40,449 shares of company stock valued at $532,889. 5.04% of the stock is owned by corporate insiders.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.